LAVI Stock Overview
Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, dermocosmetic, and healthcare products to physicians and pharmacists in Greece and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Lavipharm S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.83 |
| 52 Week High | €0.96 |
| 52 Week Low | €0.39 |
| Beta | 0.94 |
| 1 Month Change | -6.95% |
| 3 Month Change | -7.57% |
| 1 Year Change | 110.13% |
| 3 Year Change | -45.75% |
| 5 Year Change | 20.29% |
| Change since IPO | -89.53% |
Recent News & Updates
Shareholder Returns
| LAVI | GR Pharmaceuticals | GR Market | |
|---|---|---|---|
| 7D | 2.5% | 2.3% | 5.7% |
| 1Y | 110.1% | 7.5% | 29.7% |
Return vs Industry: LAVI exceeded the Greek Pharmaceuticals industry which returned 7.5% over the past year.
Return vs Market: LAVI exceeded the Greek Market which returned 29.7% over the past year.
Price Volatility
| LAVI volatility | |
|---|---|
| LAVI Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in GR Market | 8.0% |
| 10% least volatile stocks in GR Market | 2.5% |
Stable Share Price: LAVI has not had significant price volatility in the past 3 months.
Volatility Over Time: LAVI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1911 | 307 | n/a | lavipharm.com |
Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, dermocosmetic, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD.
Lavipharm S.A. Fundamentals Summary
| LAVI fundamental statistics | |
|---|---|
| Market cap | €139.33m |
| Earnings (TTM) | €2.00m |
| Revenue (TTM) | €50.93m |
69.7x
P/E Ratio2.7x
P/S RatioIs LAVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LAVI income statement (TTM) | |
|---|---|
| Revenue | €50.93m |
| Cost of Revenue | €27.73m |
| Gross Profit | €23.20m |
| Other Expenses | €21.20m |
| Earnings | €2.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.012 |
| Gross Margin | 45.55% |
| Net Profit Margin | 3.92% |
| Debt/Equity Ratio | 48.6% |
How did LAVI perform over the long term?
See historical performance and comparison